Quizartinib is an experimental drug being tested for children and young adults with a specific type of blood cancer called Acute Myeloid Leukemia (AML), which affects blood and bone marrow. Patients can join if their cancer has returned after treatment or isn’t responding to therapy. The study has several parts including dose escalation to find the right amount of the drug for younger patients, and dose expansion where this dose is tested further. Participants will receive re-induction therapy, which includes special chemotherapy medicines before trying quizartinib alone. Some patients might undergo a procedure called Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) if suitable. After HSCT, patients who show improvement will continue with quizartinib for up to 12 cycles. Long-term follow-up involves check-ups every few months to see how patients are doing. Potential participants should be between 1 month and 21 years old and meet specific health criteria.

• The study involves multiple visits and phases.
• Participants may receive special treatments like chemotherapy and HSCT.
• Regular follow-ups will assess health and treatment progress.